ARTICLE | Clinical News
Mesendo: Phase I data
September 7, 2009 7:00 AM UTC
An open-label, U.S. Phase I trial in 10 patients showed that Mesendo was safe and significantly improved quality of life in all patients at 6 months. Data were presented at the European Society of Car...